Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 7/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4591103 | 0.87 | MCHR1 (0.37) | CYP11B1CHRNB2CHRNA4ALDH1A1NPC1 | |
| SCHEMBL4590528 | 0.81 | NPC1 (0.46) | NPC1RAB9ALTA4H | |
| SCHEMBL4591441 | 0.81 | NPC1 (0.40) | CYP1A2CYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL4590894 | 0.81 | MEN1 (0.44) | CYP11B1CYP11B2CHRNB2CHRNA4ALDH1A1 | |
| SCHEMBL4591482 | 0.80 | KDM1A (0.41) | CHRM5ALDH1A1 | |
| SCHEMBL4590135 | 0.80 | ESR1 (0.39) | CHRNB2CHRNA4CHRM5NPC1RAB9A | |
| SCHEMBL4590769 | 0.80 | LMNA (0.46) | CYP19A1ALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL4590873 | 0.80 | CYP4F2 (0.35) | CHRNB2CHRNA4ALDH1A1NPC1RAB9A | |
| SCHEMBL4591402 | 0.80 | BMP4 (0.39) | CYP1A2CHRNB2CHRNA4CYP2D6NPC1 | |
| SCHEMBL4590732 | 0.80 | RAB9A (0.42) | CHRNB2CHRNA4NPC1RAB9ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1899321-B1 | HETEROARYL-SUBSTITUTED AMIDES COMPRISING A SATURATED LINKER GROUP, AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2011-12-28 | — | — | EP | claimed |
| US-20080171739-A1 | Heteroaryl-Substituted Amides Comprising A Saturated Linker Group, And Their Use As Pharmaceuticals | SANOFI-AVENTIS (FR) | 2008-07-17 | — | — | US | claimed |
| EP-1899321-A1 | HETEROARYL-SUBSTITUTED AMIDES COMPRISING A SATURATED LINKER GROUP, AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-03-19 | — | — | EP | claimed |
| WO-2007000246-A1 | HETEROARYL-SUBSTITUTED AMIDES COMPRISING A SATURATED LINKER GROUP, AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-01-04 | — | — | WO | claimed |
| US-8518976-B2 | e.g. 1-(3-(6-(2-fluorophenyl)pyridin-3-yl)propyl)-1H-pyridin-2-one; endothelial nitric oxide NO synthase inhibitor; antiinflammatory, hypotensive agent; atherosclerosis, thrombosis, coronary artery disease, and cardiac insufficiency | SANOFI (FR) | 2013-08-27 | — | — | US | disclosed |
| EP-1899321-B1 | HETEROARYL-SUBSTITUTED AMIDES COMPRISING A SATURATED LINKER GROUP, AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2011-12-28 | — | — | EP | disclosed |
| US-20080171739-A1 | Heteroaryl-Substituted Amides Comprising A Saturated Linker Group, And Their Use As Pharmaceuticals | SANOFI-AVENTIS (FR) | 2008-07-17 | — | — | US | disclosed |
| EP-1899321-A1 | HETEROARYL-SUBSTITUTED AMIDES COMPRISING A SATURATED LINKER GROUP, AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007000246-A1 | HETEROARYL-SUBSTITUTED AMIDES COMPRISING A SATURATED LINKER GROUP, AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171739-A1 | Heteroaryl-Substituted Amides Comprising A Saturated Linker Group, And Their Use As Pharmaceuticals | TBXAS1, PTGIS, NOS2 | CYP11B1 30/4885CYP11B2 51/4885CYP1A2 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.